| Abstract | Nephropathy associated with type 2 diabetes mellitus is a rising cause of end-stage renal disease and is a major public health problem. If blocking of the renin angiotensin system has a well established nephroprotective effect in type 1 diabetic nephropathy, this remained to be shown for type 2 diabetes. Two large outcome trials using angiotensin II receptor antagonists (ARA's) in proteinuric chronic renal impairment and hypertensive type 2 diabetic patients have now closed this gap: the Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) trial. Both trials showed a significant reduction in the primary pre-specified end-point of death, or worsening of renal function (doubling of serum creatinine) or the development of end-stage renal disease. This effect goes beyond the reduction in blood pressure and makes of ARA's one of the important tools in the treatment of type 2 diabetic nephropathy. |
| Authors | L Weekers, J M Krzesinski
(Affiliation: Service de Néphrologie, CHU Sart-Tilman.)
|
| Journal | Revue médicale de Liège
(Rev Med Liege)
Vol. 56
Issue 10
Pg. 723-6
(Oct 2001)
ISSN: 0370-629X Belgium |
| Vernacular Title | Etude clinique du mois. Rôle néphroprotecteur des antagonistes du récepteur de l'angiotensine II (ARA) dans le diabète de type 2: résultats des études IDNT et RENAAL. |
| PMID | 11765585
(Publication Type: English Abstract, Journal Article)
|
| Chemical References |
- Antihypertensive Agents
- Receptors, Angiotensin
- Creatinine
|
| Topics |
- Antihypertensive Agents
(pharmacology)
- Creatinine
(metabolism)
- Diabetic Nephropathies
(complications, prevention & control)
- Humans
- Hypertension, Renal
(complications)
- Kidney Failure, Chronic
(prevention & control)
- Randomized Controlled Trials as Topic
- Receptors, Angiotensin
(antagonists & inhibitors)
- Renin-Angiotensin System
(drug effects, physiology)
- Treatment Outcome
|
